2024 World Conference on Lung Cancer (WCLC) - Posters-P3.13D.11 SEZ6 Expression in Neuroendocrine Tumors

Pdf Summary

The study by Jennifer A. Marks and her team at Georgetown University investigates SEZ6 expression in small cell lung cancer (SCLC) and extrapulmonary neuroendocrine (NE) tumors. SEZ6, a cell surface protein potentially involved in neurosecretory functions, presents a possible target for novel antibody-drug conjugates, but its expression in these cancer types is not well understood.<br /><br />Using RNA sequencing, the researchers analyzed tumor samples from 1,312 SCLC and 2,231 extrapulmonary NE cancer patients. SEZ6 expression was measured and reported in transcripts per million (TPM), with tumor samples stratified into quartiles based on SEZ6 RNA levels. The study identified varied expression across different SCLC subtypes, with median SEZ6 levels highest in Mixed and SCLC-A subtypes and lowest in SCLC-P.<br /><br />The results show that SEZ6 expression is generally higher in SCLC than in extrapulmonary NE tumors, with prostate NE tumors showing the highest SEZ6 expression among extrapulmonary sites. Additionally, SEZ6 expression correlated with the expression of certain tumor markers, notably ASCL1, NEUROD1, and YAP1. This suggests a potential linkage between SEZ6 levels and specific molecular subtypes of SCLC.<br /><br />Analysis of survival data revealed that patients in the SEZ6-Q2 group had the longest median survival, compared to other quartiles. In SCLC patients, SEZ6 expression was notably higher than in non-small cell lung cancer (NSCLC).<br /><br />The findings indicate significant variation in SEZ6 expression across different tumor types and SCLC subtypes, underscoring SEZ6’s potential as a therapeutic target in NE tumors. Further investigation into SEZ6 in other NE cancers is warranted, presenting an opportunity for developing targeted therapies.

Asset Subtitle

Jennifer Marks

Meta Tag

Speaker Jennifer Marks

Topic SCLC & Neuroendocrine Tumors

Keywords

SEZ6 expression

small cell lung cancer

extrapulmonary neuroendocrine tumors

antibody-drug conjugates

RNA sequencing

tumor markers

SCLC subtypes

prostate NE tumors

molecular subtypes

targeted therapies